Price To Earnings Ratio 19.56 | Sector PE 62.71 |
PB Ratio 3.88 | Sector PB 8.93 |
EPS 334.41 | Dividend Yield 0.65 |
Today's Volume 358.025 K | 5 Day Avg. Volume 418.006 K |
PEG Ratio 0.83 | Market Cap. ₹ 1,10,000.00 Cr. |
Time | DRREDDY | VS | Industry |
---|---|---|---|
1 Day | -1.25% | -0.56% | |
1 Week | -1.46% | -0.91% | |
1 Month | -2.33% | -2.19% | |
6 Months | 2.95% | 20.91% | |
1 Year | 23.73% | 60.08% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 6691.13 | Bearish |
20 | 6659.55 | Bearish |
30 | 6740.75 | Bearish |
50 | 6800.73 | Bearish |
100 | 6489.84 | Bullish |
200 | 6274.08 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 4543.30 | 5887.50 | 2810.80 | ||||
Investing Activities | -4028.30 | -4137.30 | -2638.70 | ||||
Financing Activities | -376.30 | -2686.10 | -242.20 | ||||
Net Cash Flow | 138.70 | -935.90 | -70.10 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Dr. Reddy's Laboratories | -1.25 | -1.46 | -2.33 | 2.95 | 23.73 |
Advanced Enzyme Tech | -1.92 | -5.01 | 5.24 | 29.16 | 57.84 |
Alembic | -1.29 | 1.37 | -9.62 | 5.12 | 5.12 |
Aster DM Healthcare | -2.68 | 0.81 | 0.5 | -7.36 | 23.63 |
Divi's Laboratories | 0.11 | 0.58 | 6.05 | 51.06 | 46.58 |
Dr. Reddy's Laboratories Limited is an Indian global pharmaceutical company. The company offers a wide range of products and services, including active ingredients (APIs), generics, generic brands, biosimilars and OTC products. Its main therapeutic focus areas are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The company's segments include Pharmaceutical Services and Active Ingredients, Global Generics and others. The Pharmaceutical Services and Active Ingredients Segment consists primarily of the Company's API and intermediate manufacturing and distribution business. The Global Generics segment consists of the Company's business, which manufactures and markets prescription and over-the-counter drugs that are ready for patient consumption, marketed under a brand name (branded formulations) or generic usable dosages that are therapeutically equivalent to brand name products (generic).